Autolus Therapeutics (AUTL) EBITDA (2017 - 2025)
Historic EBITDA for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to -$84.9 million.
- Autolus Therapeutics' EBITDA fell 5412.82% to -$84.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$228.8 million, marking a year-over-year increase of 358.44%. This contributed to the annual value of -$220.8 million for FY2024, which is 1126.93% down from last year.
- Autolus Therapeutics' EBITDA amounted to -$84.9 million in Q3 2025, which was down 5412.82% from -$28.9 million recorded in Q2 2025.
- Autolus Therapeutics' 5-year EBITDA high stood at $40.5 million for Q3 2021, and its period low was -$248.9 million during Q4 2021.
- Over the past 5 years, Autolus Therapeutics' median EBITDA value was -$52.6 million (recorded in 2024), while the average stood at -$48.2 million.
- Per our database at Business Quant, Autolus Therapeutics' EBITDA soared by 9265.32% in 2022 and then plummeted by 29578.34% in 2023.
- Autolus Therapeutics' EBITDA (Quarter) stood at -$248.9 million in 2021, then skyrocketed by 92.65% to -$18.3 million in 2022, then plummeted by 295.78% to -$72.4 million in 2023, then grew by 22.78% to -$55.9 million in 2024, then crashed by 51.93% to -$84.9 million in 2025.
- Its last three reported values are -$84.9 million in Q3 2025, -$28.9 million for Q2 2025, and -$59.1 million during Q1 2025.